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Prurigo nodularis (PN) of Hyde, also known as nodular prurigo, is a chronic skin disease of unknown etiology. It is characterized by an intensely pruritic papulonodular eruptions. The hyperkeratotic lesions tend to be symmetrical and occur over the extensor surfaces of the extremities. PN has been associated with a range of systemic conditions such as HIV/AIDS, depression, gastrointestinal disorders, hypothyroidism, and hematologic malignancies. In most cases, however, the etiology is unclear \[[@CR1]--[@CR4]\]. First-line therapy for PN is comprised of topical antipruritics or corticosteroids, oral steroids, antihistamines, or certain antidepressants such as doxepin \[[@CR5]\]. Additional commonly used treatments include phototherapy, capsaicin, cyclosporine, and methotrexate \[[@CR3]\]. Recently, novel agents such as tumor necrosis factor (TNF) inhibitors alfacept and etanercept have also been prescribed \[[@CR14]\]. Most of these therapies, however, are ineffective or only provide temporary relief. Thus, alternative treatments are needed for refractory cases.

In 1965, Sheskin was the first to report on the use of thalidomide to treat a patient with PN \[[@CR6]\]. Thalidomide is a drug with numerous proposed mechanisms of action and effects, ranging from acting as a prostaglandin/histamine antagonist to being an inhibitor of fibroblast growth factor and a immunomodulatory agent \[[@CR7]\]. As an immunomodulatory drug, thalidomide functions to decrease TNF-α and inhibits polymorphonuclear leukocyte chemotaxis \[[@CR7]\]. TNF-α induces pain by increasing the production of interleukin (IL)-1b and IL-6, which then increases the production of IL-8, a known mediator of sympathetic pain \[[@CR8]--[@CR10]\]. More recently, thalidomide has also been shown to inhibit the peripheral vanilloid receptor 1 (TRVP1) channel, which is also involved in pain sensation \[[@CR11]\].

Thalidomide became well known for its teratogenic effects leading to severe fetal malformations when taken by pregnant women before the third trimester \[[@CR12]\]. This medication has other known side effects, which include peripheral neuropathy, somnolence, altered mood, thrombosis, and gastrointestinal symptoms.

Lenalidomide, a more potent analogue of thalidomide, has been most commonly used to treat multiple myeloma and myelodysplastic syndromes. Lenalidomide's molecular structure varies by one less carbonyl group but one additional amine compared to thalidomide \[[@CR13]\]. This change confers a different toxicity profile and, as such, lenalidomide has a much lower frequency of peripheral neuropathy \[[@CR14]\]. While some studies report the use of thalidomide and lenalidomide to be beneficial for the treatment of PN, their use in the management of PN remains controversial. Thus, this review aims to explore and review the efficacy and safety of thalidomide and lenalidomide for the treatment of refractory PN.

Methods {#Sec2}
=======

A systematic literature review was performed to identify articles between January 1, 1970 and February 15, 2016 relevant to the treatment of prurigo nodularis with thalidomide or lenalidomide. The terms "prurigo nodularis OR nodular prurigo OR picker's nodules OR lichen corneus obtusus OR atypical nodular form of neurodermatitis circumscripta" were searched in the National Library of Medicine's PubMed Database and returned 350 articles. Exclusion criteria included articles that were not written in English and those that were not original clinical trials, case series or case reports. Thirty manuscripts with relevant titles and abstracts were included for further review, based on case reports/series due to lack of controlled studies. If a study with a cohort or group did not distinguish patients with PN from other patients with different dermatological conditions within the same group, it was excluded. In addition, the SCOPUS Database was crosschecked, but no additional articles were found. As a result, a total of 18 articles were selected for inclusion in this review (Fig. [1](#Fig1){ref-type="fig"}). This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.Fig. 1Flowchart of search methodology. *PN* prurigo nodularis

Results {#Sec3}
=======

In the first reported case, Van de Broek et al. described a 57-year-old man with refractory PN admitted for an infection superimposed on nodules that had previously failed both topical and oral steroids as well as antihistamines \[[@CR12]\]. Thalidomide 100 mg bis in die (BID) was used for 3 months and discontinued after resolution of the pruritis and lesions. No side effects were reported.

Andersen and Fogh retrospectively reviewed 42 subjects with PN treated with thalidomide \[[@CR22]\]. Of these, 60% of patients showed clinical improvement, but 9.5% of patients showed no effect. The average daily dose was 100 mg, though a few patients received 50 mg due to gastrointestinal-related side effects. The mean duration of treatment was 105 weeks, and 59.5% of patients developed peripheral neuropathy ranging from 1 week to 7.5 years after initiation of treatment, prompting discontinuation of therapy at the time of symptom development. None of the subjects with neuropathy showed evidence of this adverse effect during follow-up.

Alfadley et al. started thalidomide 100 mg BID in a Hepatitis B patient who developed major depressive disorder and suicidal risk following a 5-year history of PN refractory to therapy \[[@CR17]\]. After 3 weeks of treatment, the pruritus had mildly decreased without improvement in skin lesions. Subsequently, the dose was increased to 300 mg daily. By the 8th month, the pruritus had ceased, the majority of lesions had cleared, and mild sensory loss developed. The patient was then placed on a maintenance dose of 50 mg every other day for 3 months. At the 4-month follow-up, the patient remained disease-free and the sensory loss had dramatically improved.

Maurer et al. performed a trial on 10 HIV-infected patients. They received thalidomide 100 mg per day and were randomized after 1 month to receive either 100 or 200 mg daily \[[@CR4]\]. Doses were adjusted if adverse events appeared, thus daily dosing ranged from 33 to 200 mg. Eight patients (80%) continued the trial longer than 1 month, and all had a greater than 50% reduction in itch, while 7 (70%) had a greater than 50% reduction in lesions. Pruritic reduction occurred within 1--3 months of treatment, while decreases in erythema and nodule size occurred between 3--6 months. Three patients (30%) developed peripheral neuropathy; however, no association with neuropathy was found between treatment duration, daily dose, or cumulative dose.

Herranz et al. also treated a case of AIDS-associated PN in a 35-year-old white male with a CD4 count of 8 cells/mm^3^ \[[@CR2]\]. Following a failed trial of topical corticosteroids and antihistamines, he was placed on thalidomide 100 mg daily for 6 weeks, upon which there was a drastic improvement of itching and lesions. The patient had a relapse of tuberculosis after 1 month of discontinuing thalidomide, which was postulated to have been due to the inhibitory effect of thalidomide on TNF-a. There were no other side effects reported.

Ferrandiz et al. conducted a prospective trial to evaluate combination therapy using thalidomide and ultraviolet-B (UVB) irradiation on four patients with PN \[[@CR15]\]. Two patients had previously undergone a course of thalidomide but subsequently relapsed. Thalidomide was started at 100 mg daily and was discontinued once significant clinical improvement was achieved, ranging from 8 to 16 weeks. UVB phototherapy was then initiated for three sessions per week until complete clearance of the nodules was achieved, with a maximum of 70 exposures allowed. Most symptoms resolved after 6--12 UVB treatments, at which point thalidomide was also discontinued. One patient developed temporary peripheral neuropathy and another developed nausea. The follow-up period ranged from 4--18 months, in which one patient experienced a relapse at 5 months, which was then successfully managed with 35 treatments of UVB irradiation.

Lenalidomide has also been used in patients experiencing toxicity with thalidomide. Kanavy et al. treated a 45-year-old black woman with a severe 10-year case of PN \[[@CR14]\]. She was first treated with thalidomide 200 mg daily and had a dramatic improvement, but she developed neuropathy after 18 months and treatment was stopped. After thalidomide, she also was treated with oral naltrexone, minocycline, gabapentin, alafecept, and etanercept with no sucess \[[@CR14]\]. Thereafter, she was started on lenalidomide 5 mg a day and by the second week she noted a significant decrease in pruritus, sleep, and concentration ability. By the first month, she exhibited healing of nodules and disappearance of itching. Two attempts were made to taper her dose and both resulted in disease flare-ups, thus she was maintained on 5 mg/day for a total of 24 months. The patient remained in remission after 2 years. Liu et al. reported another case of lenalidomide-treated refractory PN. The patient had a severe 20-year history of the disease. She was previously treated with steroids, antihistamines, and underwent psoralen + UVA therapy for 6 months with no relief. Furthermore, the latter treatment resulted in the development of squamous cell carcinomas on her lower extremities. After discontinuation of the photochemotherapy, she was started on 100 mg of thalidomide daily. By month 3, she developed tingling and numbness in all of her limb extremities and thalidomide was discontinued. After 1 month, she resumed thalidomide at 50 mg but her neuropathy returned and the medication was discontinued. Four months later, she was started orally on lenalidomide 10 mg/day with a marked reduction in nodules and itching intensity after only 1 month. Her reported adverse effects were arthralgias, nausea, and vomiting. She continued taking lenalidomide and achieved almost complete clearance until right leg weakness prompted termination of the current treatment after 3 months of lenalidomide. She had no residual neuropathy, but her PN relapsed.

Trends in Treatment, Dosage, and Length {#Sec4}
=======================================

A total of 18 studies with 106 patients treated with thalidomide or lenalidomide for PN were reviewed (see Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). It should be noted that these trends were based on case reports/series or retrospective literature due to lack of controlled studies, especially in regards to lenalidomide treatment, as only a few case reports exist. In the earlier studies, patients were started on higher doses of thalidomide of 200 mg or more daily \[[@CR5], [@CR12]\]. In the majority of studies since then, however, patients were started on an initial dose ranging from 50 to 200 mg thalidomide per day and then tailored according to response or development of side effects. Length of treatment for thalidomide ranged from 1 month to almost 12 years depending on remission of disease or discontinuation due to development of toxicity. In the study by Ferrandiz et al., patients were treated with combination therapy of thrice weekly narrow-band UVB phototherapy and thalidomide at 100 mg daily for 2.5--5 months \[[@CR15]\]. Excellent responses were achieved after an average of 3 months on thalidomide and 32 UVB courses \[[@CR15]\]. One patient that was taking lenalidomide was kept on 5 mg for over 2 years, while the other took 10 mg daily for 3 months \[[@CR11], [@CR13]\]. For lenalidomide, treatment length was from 3 to over 24 months. Lenalidomide offered a relatively low toxicity treatment to patients who had toxicity to thalidomide.Table 1Studies utilizing thalidomide for treatment of prurigo nodularisStudyPatientsM:FAge (years)Dose per day (mg)Duration (months)ResultsAdverse effectsFollow-up (months)Van de Broek \[[@CR16]\]11:054200 mg3Lesions gradually flattened and pruritus disappearedNone--Clemmensen et al. \[[@CR29]\]31:229--69200 mg\
200 mg with maintenance dose of 50 mg\
300 mg6--22Two patients reported pruritus resolved and all lesions healed. One patient showed no improvement in symptomsTwo developed paresthesias in hands after 11--18 months, one had adverse effects persist \>1 year after discontinuation. Two had asymptomatic carpal tunnel syndrome12Winkelmann et al. \[[@CR17]\]40:2 (two unknown)55, 59, (two unknown)300 mg then tapered to 100 mg\
100 mg then increased to 200 mg. After relapse, second course was maintained at 200 mg3--9All showed marked reduction in pruritus by 1 month and flattening of lesions by 2 months. Two remained in remission at 2 and 3 years follow-up, two relapsed within 2 weeks and required a second courseNo significant adverse effects. Side effects reported included indigestion, constipation, nervousness, and sedation24--48Berger et al. \[[@CR1]\]11:049200 mg then ranged from 100 to 150 mg for 9 months14At 2 months, a dramatic decrease in number of active lesions\
At 5 months, the pruritus disappearedMild peripheral neuropathy of legs that may be due to either PN or HIV medications2.75Herranz et al. \[[@CR2]\]11:035100 mg1.5Dramatic improvement of cutaneous lesions and disappearance of the pruritusNone reported1Crouch et al. \[[@CR19]\]51:423--71100 mg1--3.5Three showed improvement of lesions, two had no changeThree patients ceased treatment due to adverse events, two from peripheral neurotoxicity and one from dizziness, angina, and worsening diabetes4Alfadley et al. \[[@CR20]\]11:037100 mg b.i.d, for 3 weeks increased to 300 mg q daily for 8 months, then tapered to maintenance of 50 mg q 48 h for 3 months19After 8 months, most of the lesions and pruritus resolvedAt 8 months, developed mild sensory loss, then developed total peripheral neuropathy which prompted discontinuation. At 4-month follow-up the symptoms improved4Maurer et al. \[[@CR4]\]8----100 mg then randomized to 100 or 200 mg (range from 33 to 200 mg)1--23 (avg. 8)Eight had \>50% response in reduction of pruritus over 3.4 months (average). Seven had \>50% reduction of skin involvement over 5 months (average). Four patients were followed up for 1.5--9.5 months after treatment and three maintained a \>50% response and the last relapsedThree developed thalidomide peripheral neuropathy (one at 1 month, two at 7 months). All three improved 2--3 months after cessation. Weight gain, constipation, sedation, cognitive, and mood changes were also noted1.5--9.5Sharma et al. \[[@CR21]\]11:044100 mg for 2 weeks increased to 200 mg for 2 months2.5Complete resolution of lesionsSedation--Lan et al. \[[@CR22]\]64:240--86100 mg then tapered1.5--15All reported prominent reduction in pruritus and reduced excoriation of skin lesions. One had recurrence and was treated with a second course, which proved successfulTwo had sedation, one had generalized erythema with lower leg edema that resolved without intervention after 3 weeks0--20Doherty and Hsu \[[@CR23]\]12----100 mg tapered to 50 mg if early clinical improvementOver 1One had mild (no worsening and \<25%) improvement, six had moderate (25--90%) improvement, and one had complete (\>90%) improvementNumbness, constipation, and sedation--Orlando et al. \[[@CR24]\]10:152100 mg for 1 month, 50 mg for 2 months, then dosage increased to 100 mg for 1 month, and reduced again to maintenance of 50 or 100 mg orally alternate days6After 1 month, pruritus decreased and skin examination revealed that most lesions had disappeared or flattened. After 4 month,s dose was increased back to 100 mg and leg nodules showed significant decrease in size and numberNo significant side effects reported6Andersen et al. \[[@CR25]\]4217:25Avg. 46Avg. 100 mg daily\
Four patients decreased to 50 mg due to gastrointestinal side effectsAvg. 26.2525 patients had significant improvement, six had mild improvement, and one had complete clearing. Six had no affect and four were lost to follow-up25 reported transient peripheral neuropathy (at 89 weeks average), nine had sedation, seven had dizziness, and five described a rash--Taefehnorooz et al. \[[@CR26]\]133:1037--68 (avg. 49.7)50--100 mg for 12 patients\
150--200 mg for 1 patient3--142Seven showed complete improvement after 3 months (average) with four on maintenance treatment at last follow-up. Four showed slight improvement and treatment for two was judged to be unsuccessfulFour patients discontinued treatment due to peripheral neuropathy), renal toxicity, or sedation and dizziness. One patient lost to follow-up6--119Rishi et al. \[[@CR28]\]10:14550 mg daily initial then increased to 100 mg and then 150 mg--Significant reduction in pruritus that allowed for discontinuation of corticosteroidsExperienced peripheral neuropathy at higher doses requiring reduction to 50 mg daily--*Avg* average, *hx* history, *pts* patients, *y/o* years old, *b.i.d.* bis in dieTable 2Studies utilizing thalidomide with UVB or lenalidomide for treatment of prurigo nodularisStudyPatientsM:FAge (years)TreatmentDose per day (mg)Duration (months)ResultsAdverse effectsFollow-up (months)Ferrandiz et al. \[[@CR15]\]4--53--74Thalidomide + UVB100 mg2.5--5 monthsAfter an avg. of 3 months on thalidomide, pruritus was greatly reduced and lesions flattened. Then, after an avg. of 8 UVB sessions, most lesions had disappeared. Complete remission was achieved after an avg. of 32 UVB treatmentsOne patient had reversible peripheral neuropathy and one had nausea4--18Kanavy et al. \[[@CR14]\]10:145Lenalidomide5 mg for 4 months, decreased to every other day, then every 4th day, then increased back to 5 mg due to flare upsOver 24 monthsWithin 2 weeks, noticed significant reduction in pruritus and improvement in sleep, mood, and ability to concentrate. After 1 month, had near complete resolution of pruritus and visible healing of the prurigo nodules. When dose was lowered, the patient developed worsening pruritusInitially somnolence and fatigue, but this resolved after changing to bedtime dosing24Liu et al. \[[@CR27]\]10:164Lenalidomide10 mg3 monthsAfter 1 month, had significant reduction in number of nodules and pruritus, continued to improve over the next 2 months, but relapsed after discontinuationMild side effects (nausea, vomiting, malaise, arthralgia), and after 3 months, weakness in right leg prompted discontinuation--

Trends in Outcomes {#Sec5}
==================

A total of 106 patients were included in this review, 76 (71.7%) of whom showed significant improvement in reduction of pruritus and disappearance of nodules \[[@CR1], [@CR2], [@CR4], [@CR14]--[@CR28]\]. Only slight or mild improvement was seen in 11 (10.3%) patients \[[@CR23], [@CR25], [@CR26]\], while 15 (13.3%) patients showed no improvement at all \[[@CR19], [@CR23], [@CR25], [@CR26], [@CR29]\]. Results were unable to be determined in four patients in one retrospective study \[[@CR25]\]. Pruritus typically was the first to decrease with a noticeable clinical difference by 2--4 weeks followed by flattening of lesions and decreased excoriation which occurred at an average of 2 months. For patients who achieved complete or almost complete remission, time until that endpoint varied from as little as 1 month to as long as 8 months \[[@CR20]\].

Trends in Adverse Effects {#Sec6}
=========================

Peripheral neuropathy was the most common adverse effect. Overall, there were a reported 39 (36.8%) cases of peripheral neuropathy \[[@CR1], [@CR4], [@CR15], [@CR16], [@CR18]--[@CR20], [@CR25]--[@CR28]\] not including the additional patients affected in Doherty and Hsu's study, as the exact amount was unable to be obtained \[[@CR23]\]. Thalidomide-induced neuropathy developed after 1 week to 7.5 years of treatment \[[@CR25]\]. In most cases, the peripheral neuropathy was reversible and took up several months to resolve. Some patients with HIV/AIDS experienced peripheral neuropathy, but it was unclear if it was due to thalidomide or the HIV infection \[[@CR1]\]. Clemmensen et al. had one patient who still experienced neuropathy over a year after discontinuation; however, it should be noted that the patient used the drug for 18 months \[[@CR29]\]. Although no studies directly or extensively addressed the subject, there appears to be increased toxicity at higher doses of thalidomide \[[@CR14], [@CR20], [@CR22], [@CR26]\]. Sedation, gastrointestinal symptoms, and dizziness were the other most-often reported adverse effects.

Lenalidomide was used in two patients after they failed thalidomide therapy \[[@CR14], [@CR27]\]. The first patient discontinued thalidomide after developing peripheral neuropathy. She was then treated successfully with lenalidomide and had no recurrence of paresthesias \[[@CR14]\]. The other patient also developed tingling and decreased sensation with thalidomide; however, she eventually re-developed neuropathy after a trial of lenalidomide \[[@CR27]\]. More studies are needed to determine the outcomes of thalidomide compared to lenalidomide, and whether this could be a preferred treatment option with less side effects.

Trends in Recurrence {#Sec7}
====================

Seven patients relapsed after thalidomide-induced improvement of PN symptoms and cessation of therapy \[[@CR14], [@CR15], [@CR17], [@CR22], [@CR27]\]. Four achieved remission after a second course of completed therapy \[[@CR15], [@CR17], [@CR22]\], and one continued to have disease flare-ups with multiple attempts at tapering the dose, and thus was maintained on 5 mg/day of lenalidomide \[[@CR14]\]. The last one had to stop treatment after courses of both thalidomide and lenalidomide due to neuropathy, and relapsed without further resolution \[[@CR27]\].

Conclusion {#Sec8}
==========

Prurigo nodularis is a severely pruritic skin disease and standard therapy often yields unsatisfactory results. Thalidomide and lenalidomide can be effective alternative treatments for refractory PN, though optimal dosage and treatment time varied in the reviewed studies. Clinical data compiled in this review show that individuals with severe disease experienced the most significant reduction in pruritus and improvement in the appearance of skin. Historically, thalidomide has been used with reluctance due to toxicity; however, the incidence and persistence of adverse effects including neuropathy is highly variable among patients, in the majority of whom clinical improvement preceded the development of permanent deficit. Ideal treatment length and dosing regimens may help abate most side effects. To further avoid adverse effects, thalidomide could be used in sequential combination therapy with UVB or followed by its analogue lenalidomide. Both options shorten the treatment length for thalidomide and may limit adverse reactions; however, most studies are limited by virtue of being case reports and their low power. In the contemporary era of targeted therapy, an enhanced understanding of the biology and related physiology of PN will allow clinicians to more optimally treat this evasive disease. Additionally, understanding of the molecular mechanisms of thalidomide and lenalidomide may also further elucidate their role in the treatment of PN. Given the findings in the aforementioned studies, thalidomide and its analogues should be further evaluated in a prospective manner with the aim of improving efficacy and reducing treatment-related toxicity by determining the most effective dosing and treatment time.
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